ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Cellink AB to take-over Discover Echo Inc
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Thermo Scientific HyPerforma GXCore Bioprocess Controller
The Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.
Rheincell set to be acquired by Catalent
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
Data protection rules may block medical progress
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies bags €20m in Series A financing
NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma expands its ATMP development facilities
Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
Tube welding or aseptic connectors Which is the better connection method?
Which connection method do most industry professionals prefer: tube welding or aseptic connectors? A recent survey revealed their preferences are almost equally split between the two. But that doesn’t mean one method might not be better for your needs.
Including China in your global drug development strategy
The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?
mRNA: Evonik cooperates with Stanford University
Company seeks new opportunities for use of mRNA therapeutics.